Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mesoblast (MESO) EBITDA (2016 - 2023)

Historic EBITDA for Mesoblast (MESO) over the last 9 years, with Q2 2023 value amounting to $3.0 billion.

  • Mesoblast's EBITDA rose 36.0% to $3.0 billion in Q2 2023 from the same period last year, while for Jun 2023 it was $687.7 million, marking a year-over-year increase of 542984.08%. This contributed to the annual value of -$62.0 million for FY2025, which is 553.46% down from last year.
  • Mesoblast's EBITDA amounted to $3.0 billion in Q2 2023, which was up 36.0% from -$1.2 billion recorded in Q1 2023.
  • Mesoblast's EBITDA's 5-year high stood at $7.0 billion during Q2 2021, with a 5-year trough of -$1.6 billion in Q1 2021.
  • In the last 5 years, Mesoblast's EBITDA had a median value of -$541.9 million in 2019 and averaged $298.4 million.
  • As far as peak fluctuations go, Mesoblast's EBITDA surged by 1956610.37% in 2020, and later plummeted by 1187267.58% in 2021.
  • Mesoblast's EBITDA (Quarter) stood at -$734.6 million in 2019, then skyrocketed by 101.37% to $10.0 million in 2020, then tumbled by 9855.66% to -$978.4 million in 2021, then rose by 15.18% to -$829.8 million in 2022, then soared by 458.51% to $3.0 billion in 2023.
  • Its EBITDA was $3.0 billion in Q2 2023, compared to -$1.2 billion in Q1 2023 and -$829.8 million in Q4 2022.